Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WARREN D SPINNER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1164617544
CMS profile
233918
Location
PORT JEFFERSON STATION, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$134,015.01

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WARREN D SPINNER

NPI 1164617544 · CMS profile ID 233918

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PORT JEFFERSON STATION, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164617544?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WARREN D SPINNER, NPI 1164617544, CMS profile ID 233918. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164617544?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WARREN D SPINNER, NPI 1164617544, CMS profile ID 233918. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164617544?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WARREN D SPINNER, NPI 1164617544, CMS profile ID 233918, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1164617544?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $134,015.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1,750.0010/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082035 CMS
Merz Pharmaceuticals, LLC $32.8210/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845436121 CMS
Amgen Inc. $2,850.0010/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825864687 CMS
Biogen, Inc. $24.3909/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827794637 CMS
Amgen Inc. $124.1609/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825864691 CMS
UCB, Inc. $28.4109/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807403115 CMS
AbbVie Inc. $96.9909/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082031 CMS
AbbVie Inc. $2,400.0009/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082033 CMS
PFIZER INC. $27.0909/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833282327 CMS
Allergan, Inc. $4,680.0009/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954255 CMS
SK Life Science, Inc. $24.7809/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826837359 CMS
Biohaven Pharmaceuticals, Inc. $23.5509/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631829 CMS
Allergan, Inc. $2,880.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954249 CMS
Allergan, Inc. $468.0509/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954251 CMS
Allergan, Inc. $124.3309/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954253 CMS
Lundbeck LLC $14.7209/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845936217 CMS
Horizon Therapeutics plc $22.3609/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797212193 CMS
AbbVie Inc. $23.3809/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082029 CMS
Sunovion Pharmaceuticals Inc. $9.8009/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821895031 CMS
AbbVie Inc. $82.9208/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082023 CMS
AbbVie Inc. $41.6708/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082025 CMS
AbbVie Inc. $2,400.0008/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082027 CMS
Novartis Pharmaceuticals Corporation $16.8808/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813284255 CMS
Allergan, Inc. $12.1208/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954247 CMS
AbbVie Inc. $25.0008/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082021 CMS
Biohaven Pharmaceuticals, Inc. $2,550.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631825 CMS
Biohaven Pharmaceuticals, Inc. $125.0008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631827 CMS
Allergan, Inc. $11.3008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954245 CMS
AbbVie Inc. $55.8308/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082015 CMS
AbbVie Inc. $55.7708/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082017 CMS
AbbVie Inc. $2,400.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082019 CMS
AbbVie Inc. $20.0008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082013 CMS
Biohaven Pharmaceuticals, Inc. $1,275.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631823 CMS
PFIZER INC. $22.6707/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833283217 CMS
Allergan, Inc. $4.9407/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954243 CMS
Teva Pharmaceuticals USA, Inc. $125.0007/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839424391 CMS
Teva Pharmaceuticals USA, Inc. $2,860.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839424393 CMS
Amgen Inc. $8.1607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825864671 CMS
Eisai Inc. $22.0107/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845771613 CMS
AbbVie Inc. $20.8307/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082007 CMS
AbbVie Inc. $2,400.0007/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082009 CMS
AbbVie Inc. $102.8607/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082011 CMS
Allergan, Inc. $1.8507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954241 CMS
Biohaven Pharmaceuticals, Inc. $2,550.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631819 CMS
Biohaven Pharmaceuticals, Inc. $117.3507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852631821 CMS
GENZYME CORPORATION $22.0407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843580019 CMS
AbbVie Inc. $23.3807/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796082005 CMS
Sunovion Pharmaceuticals Inc. $11.5007/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821882287 CMS
Allergan, Inc. $124.5907/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954237 CMS
Allergan, Inc. $2,400.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792954239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $104,998.78 276
PY2020 $93,533.92 250
PY2021 $134,015.01 217
PY2022 $146,565.33 271
PY2023 $114,875.00 265
PY2024 $111,527.49 267
PY2025 $85,119.38 188

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $367,133.37 41
PY2024 Recipient $1,911.42 2
PY2024 Principal investigator $433,115.30 53
PY2023 Recipient $157,443.11 15
PY2023 Principal investigator $246,860.21 42
PY2022 Principal investigator $300,494.67 47
PY2021 Principal investigator $42,084.76 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $350.00 12/31/2025 Non-covered Recipient Entity
TRUE NORTH SUFFOLK NEUROLOGY
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534427
Principal investigator 1 PFIZER INC. $5,260.75 11/20/2025 Non-covered Recipient Entity
True North Medical at North Suffolk PLLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729006
Principal investigator 1 H. Lundbeck A S $1,826.14 11/12/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251777056
Principal investigator 1 H. Lundbeck A S $16,036.79 10/29/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251776433
Principal investigator 1 H. Lundbeck A S $20,168.17 10/24/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251776285
Principal investigator 1 H. Lundbeck A S $5,417.69 10/22/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251775899
Principal investigator 1 ABBVIE INC. $12,000.00 10/09/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202513727
Principal investigator 1 H. Lundbeck A S $8,000.00 10/03/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251775203
Principal investigator 1 H. Lundbeck A S $2,500.00 10/03/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251775208
Principal investigator 1 Eli Lilly and Company $505.00 09/30/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884826
Principal investigator 1 H. Lundbeck A S $3,715.47 09/05/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251774366
Principal investigator 1 PFIZER INC. $2,227.00 09/04/2025 Non-covered Recipient Entity
True North Medical at North Suffolk PLLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743203
Principal investigator 1 H. Lundbeck A S $9,747.94 08/06/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251773230
Principal investigator 1 PFIZER INC. $7,500.00 08/04/2025 Non-covered Recipient Entity
True North Medical at North Suffolk PLLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228752656
Principal investigator 1 H. Lundbeck A S $6,951.02 08/01/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251773129
Principal investigator 1 H. Lundbeck A S $2,263.55 07/09/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771891
Principal investigator 1 PFIZER INC. $12,750.00 06/26/2025 Non-covered Recipient Entity
True North Medical at North Suffolk PLLC
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228774336
Principal investigator 1 PFIZER INC. $14,238.75 06/13/2025 Non-covered Recipient Entity
True North Medical at North Suffolk PLLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228776636
Principal investigator 1 Eli Lilly and Company $9,921.00 06/03/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187892880
Principal investigator 1 PFIZER INC. $3,500.00 05/28/2025 Non-covered Recipient Entity
North Suffolk Neurology PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228764993
Principal investigator 1 PFIZER INC. $14,947.80 05/15/2025 Non-covered Recipient Entity
North Suffolk Neurology PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228762713
Principal investigator 1 PFIZER INC. $5,609.50 05/15/2025 Non-covered Recipient Entity
North Suffolk Neurology PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228778342
Principal investigator 1 H. Lundbeck A S $187.50 05/07/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251770073
Principal investigator 1 H. Lundbeck A S $6,350.39 05/02/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251770027
Principal investigator 1 H. Lundbeck A S $15,430.50 05/02/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251770031
Principal investigator 1 PFIZER INC. $22,946.76 03/27/2025 Non-covered Recipient Entity
North Suffolk Neurology PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767955
Principal investigator 1 Eli Lilly and Company $8,270.00 02/11/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893202
Principal investigator 1 H. Lundbeck A S $3,733.70 02/07/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251767207
Principal investigator 1 H. Lundbeck A S $14,872.81 02/07/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251767226
Principal investigator 1 Eli Lilly and Company $4,092.55 01/31/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885314
Principal investigator 1 Eli Lilly and Company $576.00 01/31/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187889258
Principal investigator 1 Eli Lilly and Company $129.62 01/30/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187893628
Principal investigator 1 Eli Lilly and Company $1,521.00 01/22/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187891630
Principal investigator 1 H. Lundbeck A S $5,000.00 01/22/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251766638
Principal investigator 1 H. Lundbeck A S $1,500.00 01/22/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251766642
Principal investigator 1 H. Lundbeck A S $1,158.30 01/22/2025 Non-covered Recipient Entity
MULTICARE NEUROSCIENCE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251766647
Principal investigator 1 Eli Lilly and Company $28,789.00 01/21/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187891458
Principal investigator 1 Eli Lilly and Company $77,753.00 01/21/2025 Non-covered Recipient Entity
TRUE NORTH MED AT N SUFFOLK PPLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187891460
Principal investigator 1 Eli Lilly and Company $1,331.18 01/20/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885316
Principal investigator 1 Eli Lilly and Company $3,352.55 01/09/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187886430
Principal investigator 1 Eli Lilly and Company $4,701.94 01/09/2025 Non-covered Recipient Entity
NORTH SUFFOLK NEUROLOGY
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187886432